COMBINED GENETIC POLYMORPHISMS OF LDLR AND IL28B FOR PREDICTING RESPONSE TO TREATMENT WITH PEGYLATED INTERFERON PLUS RIBAVIRIN IN PATIENTS INFECTED WITH THE HEPATITIS C VIRUS

摘要

The invention relates to the use of the genetic polymorphisms rs2738456, rs2738457, rs2569540, rs2738459, rs2738460, rs2116898, and rs6413504 of the gene LDLR, for predicting or forecasting response to treatment with pegylated interferon plus ribavirin in patients infected with HCV.